Myeloproliferative disorders in older people

Reviews in Clinical Gerontology

Volumn 22, Issue 2, 2012, Pages 108-118

  Osborne, Wendy ^a   Jones, Gail L ^a   Jackson, Graham H ^a   Marr, Helen ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

chronic myeloid leukaemia; elderly; essential thrombocythaemia; myelofibrosis; myeloproliferative; polycythaemia vera

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANDROGEN; HYDROXYUREA; IMATINIB; STEROID; THALIDOMIDE;

ACUTE LEUKEMIC TRANSFORMATION; AGED; AGING; BONE MARROW SUPPRESSION; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CYTOPENIA; DIARRHEA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; MOOD CHANGE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NAUSEA; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PIGMENT DISORDER; POLYCYTHEMIA VERA; REVIEW; SIDE EFFECT; SKIN ULCER; SYMPTOM; THROMBOCYTHEMIA;

EID: 84857973967     PISSN: 09592598     EISSN: 14699036     Source Type: Journal    
DOI: 10.1017/S0959259811000256     Document Type: Review

References (35)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372-75.
2. Swerdlow H, Campo E, Harris NL et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th edn). Lyon: International Agency for Research on Cancer, 2008.
3. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45-52.
4. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythaemia beyond the first decade: life expectancy, long-term complication rates and prognostic factors. Mayo Clin Proc 2006; 81: 159-66.
5. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL negative myeloproliferative disorders. Leukemia 2008; 22: 905-14.
6. Nowell PC, Hungerford DA. Chromosome studies on normal and leukaemic human leukocytes. J Natl Cancer Inst 1960; 25: 85-109.
7. Sawyers CL. Chronic myeloid leukaemia review. N Engl J Med 1999; 340: 1330-40.
8. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in the understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009; 59: 171-91.
9. Scott LM, Beer PA, Bench AJ, Erber WN, Green AR. Prevalence of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol 2007; 139: 511-12.
10. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. (2006). MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-76.
11. McMullin MF, Reilly JT, Campbell P, Bareford D,Green AR, Harrison CN, Conneally E; National Cancer Research Institute, Myeloproliferative Disorder Subgroup, Ryan K; British Committee for Standards in Haematology. Amendment to the guideline for diagnosis and investigation of polycythaemia/ erythrocytosis. Br J Haematol 2007; 138: 21-22.
12. McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hematol 2008; 30: 447-59.
13. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythaemia vera. N Engl J Med 2004; 350: 114-24.
14. McMullin MF, Bareford D, Campbell P. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005; 130: 174-95.
15. Pearson TC, Wetherley-Main G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978; 312: 1219-22.
16. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117: 755-61.
17. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A,Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224-32.
18. Beer PA, Erber WN, Campbell PJ, Green AR. How I treat essential thrombocythemia. Blood 2011; 117: 1472-82.
19. Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, Erber W, Everington T, Green AR, Hall GW, Hunt BJ, Ludlam CA, Murrin R, Nelson-Piercy C, Radia DH, Reilly JT, Van der Walt J, Wilkins B, McMullin MF; British Committee for Standards in Haematology. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149: 352-75.
20. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999; 61: 10-15.
21. Osborne WL, Wilkins B, Lennard AL. Cutaneous extramedullary hemopoiesis in myelofibrosis. Available at: http://www.bloodmed.com/ education/case1.asp?id= 127 (accessed 21 October 2011).
22. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-LarránA, Rambaldi A, Finazzi G, Barosi G. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115: 778-82.
23. Visani G, Finelli C, Castelli U et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990; 75: 4-9.
24. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanai A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol 2008; 83: 363-65.
25. Besa EC, Nowell PC, Gella NL, Gardner FH. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 1982; 49: 308-13.
26. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and pre-operative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361-70.
27. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-901.
28. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukaemic transformation in myelofibrosis with myeloid metaplasia: a single institution experience with 91 cases. Blood 2005; 105: 973-77.
29. British Committee for Standards in Haematology 2007. Recommendations for the management of BCR-ABL positive chronic myeloid leukaemia. Available at: http://www.bcshguidelines.com/ documents/CML-BCR-ABL-270707.pdf (accessed 21 October 2011).
30. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
31. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators. Five year follow-up of patients receiving imatanib for CML. N Engl J Med 2006; 355: 2408-17.
32. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in 'good-risk' chronic granulocyticleukemia. Blood 1984; 63: 789-99.
33. Goldman G. How I treat chronic myeloid leukaemia in the imatinib era. Blood 2007; 110: 2828-37.
34. Chen AT, Prchal JT. JAK 2 kinase inhibitors and myeloproliferative disorders. Curr Opin Hematol 2010; 17: 110-16.
35. Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J, McQuaker G, Marks DI, Craddock C, McCann S, Russell N, Cook G, Kottaridis PD; British Society for Blood and Marrow Transplantation. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 2010; 45: 1587-93.